

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16  
UNDER THE SECURITIES EXCHANGE ACT OF 1934**

For the month of **July 2022**

Commission File Number: **001-39034**

**BELLUS HEALTH INC.**  
*(Name of registrant)*

**275 Armand-Frappier Blvd.**  
**Laval, Québec**  
**H7V 4A7**  
**Canada**  
*(Address of principal executive offices)*

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

### **Termination of Open Market Sale Agreement**

On July 13, 2022, BELLUS Health Inc. (“BELLUS”) agreed with Jefferies LLC (“Jefferies”) to terminate, effective July 13, 2022, the Open Market Sale Agreement<sup>SM</sup> (the “Sale Agreement”) dated December 23, 2020, between BELLUS and Jefferies. BELLUS did not make any sales of its common shares under the Sale Agreement.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

BELLUS Health Inc.

Date: July 13, 2022

By: /s/ Ramzi Benamar

Name: Ramzi Benamar

Title: Chief Financial Officer

---